Cadrenal Therapeutics
NASDAQ: CVKDPonte Vedra, US · Founded 2022 · Delaware corporation
Cadrenal Therapeutics is a clinical-stage biopharmaceutical company developing anticoagulation and antithrombotic therapies for cardiovascular and thrombotic disorders. Its pipeline includes CAD-1005, a first-in-class 12-LOX inhibitor for heparin-induced thrombocytopenia, tecarfarin for end-stage kidney disease and LVAD patients, and frunexian, an intravenous Factor XIa inhibitor for acute/critical care settings.</parameter> <parameter name="founders">[]
BiotechHealthtechMedical Devices
Founders & leadership
Cadrenal Therapeutics was founded in 2022 by Quang Pham.
QP
Quang PhamFounder
JC
Jeff ColeExecutive
MS
Matthew SzotExecutive
DW
Douglas W. LosordoExecutive
JP
John P. SharpInterim Chief Financial Officer
JJ
James J. FergusonChief Medical Officer
JS
Jeffrey S. ColeChief Operating Officer
Board
SZ
Steven ZelenkofskeBoard director
JR
John R. MurphyBoard director
GW
Glynn WilsonBoard director
RL
Robert LisickiBoard director
LG
Lee GoldenBoard director
Reported raises · per SEC filings
Form D private placements$38.5M disclosed across 7 rounds · 2022–2026
▶$8.8MraisedJul 2026 · 1 investors · BiotechnologyRule 506(b)
▶$8.8MraisedJul 2026 · 1 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Quang X. PhamExecutive Officer, Director
- John P. SharpExecutive Officer
- James J. FergusonExecutive Officer
- Jeffrey S. ColeExecutive Officer
- Lee GoldenDirector
- John R. MurphyDirector
- Glynn WilsonDirector
- Offering amount
- $8.8M
- Amount sold
- $8.8M
- Sales commissions
- $315K
- Placement agents
- H.C. Wainwright & Co., LLC
- First sale
- Jun 2026
- Incorporated
- Corporation, Delaware, 2022
- Federal exemptions
- 06b
▶$7.9MraisedApr 2026 · 1 investors · BiotechnologyRule 506(b)
▶$7.9MraisedApr 2026 · 1 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- James FergusonExecutive Officer
- Matthew SzotExecutive Officer
- Lee GoldenDirector
- John R. MurphyDirector
- Glynn WilsonDirector
- Steven ZelenkofskeDirector
- Quang X. PhamExecutive Officer, Director
- Jeffrey ColeExecutive Officer
- Offering amount
- $7.9M
- Amount sold
- $7.9M
- Sales commissions
- $296.7K
- Placement agents
- H.C. Wainwright & Co., LLC
- First sale
- Apr 2026
- Incorporated
- Corporation, Delaware, 2022
- Federal exemptions
- 06b
▶$4.4MraisedDec 2025 · 4 investors · BiotechnologyRule 506(b)
▶$4.4MraisedDec 2025 · 4 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- JOHN R. MURPHYDirector
- LEE S. GOLDENDirector
- MATTHEW K. SZOTExecutive Officer
- JEFFREY COLEExecutive Officer
- QUANG X. PHAMExecutive Officer, Director
- JAMES J. FERGUSONExecutive Officer
- GLYNN WILSONDirector
- STEVEN ZELENKOFSKEDirector
- Offering amount
- $4.4M
- Amount sold
- $4.4M
- Sales commissions
- $157.5K
- Placement agents
- H.C. Wainwright & Co., LLC
- First sale
- Dec 2025
- Incorporated
- Corporation, Delaware, 2022
- Federal exemptions
- 06b
▶$9.4MraisedNov 2024 · 5 investors · BiotechnologyRule 506(b)
▶$9.4MraisedNov 2024 · 5 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Steven ZelenkofskeDirector
- John R. MurphyDirector
- Jeff ColeExecutive Officer
- Glynn WilsonDirector
- Matthew SzotExecutive Officer
- Douglas W. LosordoExecutive Officer
- Quang PhamExecutive Officer, Director
- Robert LisickiDirector
- Offering amount
- $9.4M
- Amount sold
- $9.4M
- Sales commissions
- $468K
- Placement agents
- H.C. Wainwright & Co., LLC
- First sale
- Nov 2024
- Incorporated
- Corporation, Delaware, 2022
- Federal exemptions
- 06b
▶$7.5MraisedJul 2023 · 1 investors · BiotechnologyRule 506(b)
▶$7.5MraisedJul 2023 · 1 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Quang PhamExecutive Officer, Director
- Glynn WilsonDirector
- STEVEN ZELENKOFSKEDirector
- John MurphyDirector
- Matthew SzotExecutive Officer
- Douglas LosordoExecutive Officer
- Offering amount
- $7.5M
- Amount sold
- $7.5M
- Sales commissions
- $421.9K
- Placement agents
- H.C. Wainwright & Co., LLC
- First sale
- Jul 2023
- Incorporated
- Corporation, Delaware, 2022
- Federal exemptions
- 06b
▶$250KraisedDec 2022 · 2 investors · BiotechnologyRule 506(b)
▶$250KraisedDec 2022 · 2 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Quang PhamExecutive Officer, Director
- Douglas LosordoExecutive Officer
- Matthew SzotExecutive Officer
- Offering amount
- $1M
- Amount sold
- $250K
- Minimum investment
- $125K
- Sales commissions
- $21.2K
- Placement agents
- Boustead Securities, LLC, Sutter Securities Incorporated
- First sale
- Nov 2022
- Incorporated
- Corporation, Delaware, 2022
- Federal exemptions
- 06b
▶$150KraisedJul 2022 · 2 investors · BiotechnologyRule 506(b)
▶$150KraisedJul 2022 · 2 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Quang PhamExecutive Officer, Director
- Matthew SzotExecutive Officer
- Offering amount
- $2M
- Amount sold
- $150K
- Minimum investment
- $25K
- Sales commissions
- $76K
- Placement agents
- Sutter Securities Incorporated, Boustead Securities, LLC
- First sale
- Jul 2022
- Incorporated
- Corporation, Delaware, 2022
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Competitors · 6
by search overlap
Robinhood17 shared keywordsRobinhood is a financial trading platform that enables users to manage portfolios across stocks, ETFs, cryptocurrencies, options, futures, and prediction markets. The platform serves retail investors with low barriers to entry, offering portfolio management services and market insights.
Public16 shared keywordsPublic is a trading platform that allows users to buy and sell cryptocurrencies including Bitcoin, Ethereum, and memecoins through accounts managed by Zero Hash LLC, a New York State-licensed virtual currency business.
Tradingview15 shared keywordsTradingView is a charting platform and social network used by over 100 million traders and investors worldwide to analyze and trade across global financial markets. The platform provides tools for technical analysis, market data, and community collaboration for retail and institutional traders.
Perplexity14 shared keywordsAn AI-powered answer engine providing accurate, trusted, and real-time answers to questions.
Seeking Alpha14 shared keywordsSeeking Alpha is a financial research platform that provides stock analysis, investment tools, and market coverage across asset classes to investors. The platform aggregates research from thousands of analysts and investors, offering ratings, articles, and investment ideas.
TipRanks13 shared keywordsFinancial analysis and stock research platform.
Companies competing with Cadrenal Therapeutics for the same Google search keywords, organic and paid, via search-intersection analysis.
In the news
Cadrenal Therapeutics Solidifies Multi-Indication Strategy for CAD-1005 in Cardiac Acute Critical Care Following Competitor’s Phase 3 Discontinuation - BioSpacebiospace.com · Aug 2026Frequently asked questions
- What does Cadrenal Therapeutics do?
- Cadrenal Therapeutics is a clinical-stage biopharmaceutical company developing anticoagulation and antithrombotic therapies for cardiovascular and thrombotic disorders. Its pipeline includes CAD-1005, a first-in-class 12-LOX inhibitor for heparin-induced thrombocytopenia, tecarfarin for end-stage kidney disease and LVAD patients, and frunexian, an intravenous Factor XIa inhibitor for acute/critical care settings.</parameter> <parameter name="founders">[]
- Who founded Cadrenal Therapeutics?
- Cadrenal Therapeutics was founded by Quang Pham in 2022.
- How much funding has Cadrenal Therapeutics raised?
- Cadrenal Therapeutics has disclosed $38.5M raised across 7 rounds.
- Where is Cadrenal Therapeutics headquartered?
- Cadrenal Therapeutics is headquartered in Ponte Vedra, US.